Benjamin Dannenmann
Overview
Explore the profile of Benjamin Dannenmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nasri M, Dannenmann B, Doll L, Findik B, Bernhard F, Kandabarau S, et al.
Mol Ther
. 2024 Dec;
PMID: 39653038
Severe congenital neutropenia (CN) patients require life-long treatment with recombinant human granulocyte colony-stimulating factor (rhG-CSF), but some show no response. We sought to establish a therapy for CN that targets...
2.
Borbaran Bravo N, Deordieva E, Doll L, ElGamacy M, Dannenmann B, Azevedo J, et al.
Blood
. 2024 Dec;
PMID: 39642330
We have identified a new inherited bone marrow (BM) failure syndrome with severe congenital neutropenia (CN) caused by autosomal recessive mutations in the coatomer protein complex I (COPI) subunit zeta...
3.
Ritter M, Nasri M, Dannenmann B, Mir P, Secker B, Amend D, et al.
CRISPR J
. 2024 Oct;
7(5):258-271.
PMID: 39436283
Safety considerations for gene therapies of inherited preleukemia syndromes, including severe congenital neutropenia (CN), are paramount. We compared several strategies for CRISPR/Cas9 gene editing of autosomal-dominant mutations in CD34 cells...
4.
Nasri M, Ritter M, Mir P, Dannenmann B, Kaufmann M, Arreba-Tutusaus P, et al.
Mol Ther
. 2024 Apr;
32(6):1628-1642.
PMID: 38556793
Severe congenital neutropenia (CN) is an inherited pre-leukemia bone marrow failure syndrome commonly caused by autosomal-dominant ELANE mutations (ELANE-CN). ELANE-CN patients are treated with daily injections of recombinant human granulocyte...
5.
Xu Y, Nasri M, Dannenmann B, Mir P, Zahabi A, Welte K, et al.
Stem Cell Res Ther
. 2023 Oct;
14(1):299.
PMID: 37858174
No abstract available.
6.
Zeidler A, Borbaran-Bravo N, Dannenmann B, Ritter M, Nasri M, Klimiankou M, et al.
Haematologica
. 2023 Oct;
109(5):1393-1402.
PMID: 37855057
Mutations in the ELANE gene, encoding the neutrophil elastase (NE) protein, are responsible for most cyclic neutropenia (CyN) cases and approximately 25% of congenital neutropenia (CN) cases. In CN and...
7.
Dannenmann B, Klimiankou M, Oswald B, Solovyeva A, Mardan J, Nasri M, et al.
Cell Stem Cell
. 2023 Sep;
30(9):1282.
PMID: 37683606
No abstract available.
8.
Dannenmann B, Zahabi A, Mir P, Oswald B, Bernhard R, Klimiankou M, et al.
Exp Hematol
. 2022 Aug;
114:61.
PMID: 35952718
No abstract available.
9.
Generation, expansion, and drug treatment of hematopoietic progenitor cells derived from human iPSCs
Dannenmann B, Skokowa J
STAR Protoc
. 2022 May;
3(2):101400.
PMID: 35600931
Severe congenital neutropenia (CN) is a pre-leukemic bone marrow failure syndrome that can progress to acute myeloid leukemia (CN/AML). Patient material to study leukemogenesis, especially hematopoietic progenitor cells (HPCs) is...
10.
Dannenmann B, Klimiankou M, Oswald B, Solovyeva A, Mardan J, Nasri M, et al.
Cell Stem Cell
. 2021 Apr;
28(5):906-922.e6.
PMID: 33894142
Severe congenital neutropenia (CN) is a pre-leukemic bone marrow failure syndrome that can evolve to acute myeloid leukemia (AML). Mutations in CSF3R and RUNX1 are frequently observed in CN patients,...